Table 2.
Cumulative incidence functions for competing events in patients receiving chemotherapy or stem-cell transplantation within the high and low minimal residual disease groups
| Patients (%) |
Log-rank analysis |
Gray's test |
Univariate Cox regression analysis (Mantel-Byar method) |
Competing risk regression |
||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Progression-free survival (95% CI) | p value | Overall survival (95% CI) | p value | Cumulative incidence of relapse | p value | Progression-free survival, hazard ratio (95% CI) | Overall survival | Subdistribution hazard ratio | ||
| High minimal residual disease | ||||||||||
| Chemotherapy | 11 (11%) | 31 (11–56) | 0·13 | 54 (28–75) | 0·37 | 50 (16–77) | 0·034 | 1 | 1 | 1 |
| Stem-cell transplantation | 92 (89%) | 54 (34–71) | .. | 59 (36–75) | .. | 22 (14–31) | .. | 0·57 (0·28–1·19), p=0·13 | 0·69 (0·31–1·56), p=0·38 | 0·36 (0·16–0·83), p=0·016 |
| Low minimal residual disease | ||||||||||
| Chemotherapy | 70 (86%) | 70 (57–79) | 0·20 | 85 (74–92) | 0·74 | 26 (16–38) | 0·23 | 1 | 1 | 1 |
| Stem-cell transplantation | 11 (14%) | 88 (39–98) | .. | 100 | .. | 13 (5–44) | .. | 0·29 (0·04–2·15), p=0·23 | 0·71 (0·09–5·56), p=0·74 | 0·32 (0·04–2·36), p=0·27 |
High minimal residual disease defined as ≥10−4 cells. Low minimal residual disease defined as <10−4 cells. To compare the prognostic effect of chemotherapy with stem-cell transplantation, the Mantel-Byar method was applied in which time starts at the moment of treatment initiation, and all patients begin in the non-transplantation group. Those who receive the transplant enter the transplantation group at the time of transplantation and remain there until death, second relapse, or censoring.